BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 7514976)

  • 1. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Bryson HM
    Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
    Chapman TM; Perry CM
    Am J Respir Med; 2003; 2(1):75-107. PubMed ID: 14720024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefepime: a new fourth-generation cephalosporin.
    Okamoto MP; Nakahiro RK; Chin A; Bedikian A; Gill MA
    Am J Hosp Pharm; 1994 Feb; 51(4):463-77; quiz 541-2. PubMed ID: 8017411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefepime.
    Cunha BA; Gill MV
    Med Clin North Am; 1995 Jul; 79(4):721-32. PubMed ID: 7791419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefepime clinical pharmacokinetics.
    Okamoto MP; Nakahiro RK; Chin A; Bedikian A
    Clin Pharmacokinet; 1993 Aug; 25(2):88-102. PubMed ID: 8403741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Heel RC
    Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefepime: a fourth-generation parenteral cephalosporin.
    Wynd MA; Paladino JA
    Ann Pharmacother; 1996 Dec; 30(12):1414-24. PubMed ID: 8968455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Brogden RN
    Drugs; 1985 Feb; 29(2):105-61. PubMed ID: 3884319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a rationale for the continuous infusion of cefepime? A multidisciplinary approach.
    Bernard E; Breilh D; Bru JP; Chiche D; Dujardin I; Garraffo R; Goldstein F; Lavrard I; Potel G
    Clin Microbiol Infect; 2003 May; 9(5):339-48. PubMed ID: 12848746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacteriologic and clinical applications of a new extended-spectrum parenteral cephalosporin.
    Segreti J; Levin S
    Am J Med; 1996 Jun; 100(6A):45S-51S. PubMed ID: 8678097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.
    Wiseman LR; Benfield P
    Drugs; 1993 Feb; 45(2):295-317. PubMed ID: 7681376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefepime.
    Hardin TC; Jennings TS
    Pharmacotherapy; 1994; 14(6):657-68. PubMed ID: 7885968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections.
    Holloway WJ; Palmer D
    Am J Med; 1996 Jun; 100(6A):52S-59S. PubMed ID: 8678098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
    Brogden RN; Spencer CM
    Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.
    Ramphal R; Gucalp R; Rotstein C; Cimino M; Oblon D
    Am J Med; 1996 Jun; 100(6A):83S-89S. PubMed ID: 8678102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
    Perry CM; Scott LJ
    Drugs; 2004; 64(13):1433-64. PubMed ID: 15212560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Richards DM; Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1984 Jun; 27(6):469-527. PubMed ID: 6329638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.